Mike Boggs is a Managing Partner and Firm Administrator at Revelation Partners, a dedicated secondary investor in the healthcare space. With over $900 million of committed capital, Revelation Partners provides customized capital and liquidity solutions to healthcare investors, companies, founders, and funds.
Mr. Boggs has been involved in Revelation Partners alternative financing strategy for fourteen years, executing over $400 million in secondary and direct investments.
Some of Mr. Boggs’ current and past investments include: 23andMe (ME), Adaptive Biotechnologies (ADPT), Arcadia, AngioScore (acquired by Spectranetics), ClearCorrect (acquired by Straumann), CardioMems (acquired by St. Jude), ColoreScience, ePocrates (acquired by Athenahealth), Estech (acquired by Atricure), Grand Rounds, Nuvolo, Singular Genomics (OMIC), Surgiquest (acquired by Conmed), Prolacta, Progyny (PGNY), Pulmonx (LUNG), Raindance (acquired by BioRad), Viewray (VRAY) and TEI Biosciences (acquired by Integra Life Sciences).
Mr. Boggs is currently a board member or Observer at Nuvolo, HealthReveal and Vertos Medical and served on the boards of Singular Genomics, ClearCorrect, Angioscore, Estech, and Raindance prior to their acquisitions or IPO.
Mr. Boggs was previously a vice president at Saints Capital where he originated and valued investments in the healthcare and consumer related technology sectors. Prior to joining Saints Capital, Mr. Boggs worked within the Healthcare Group at RBC Capital Markets where he executed over $1 billion in both private and public transactions.